Trace Biosciences Inc. — SEC Form D Filing

Trace Biosciences Inc. filed an SEC Form D on August 12, 2026, reporting $8.33M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
August 12, 2026
Amount reported
$8.33M
Round stage
Seed
Industry
Medical Devices
Website
https://www.trace-bio.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Surgical nerve damage is a widespread problem causing chronic pain and loss of function, primarily because nerves are largely invisible during surgery, leading to accidental injury.

Solution

Trace Biosciences develops targeted imaging agents called Nerve Trace that highlight nerves in real time, making them visible to surgeons and robots, even when obscured by tissues and blood.

Why now

Advancements in medical imaging and fluorescence-guided surgery techniques are enabling new ways to improve surgical safety and precision. The increasing awareness and costs associated with surgical nerve injuries highlight the need for better preventative measures.

Verdict

Investors funded this seed round betting on the immediate, tangible reduction of a high-consequence surgical error. The narrative cleared because it offered a direct solution to a known problem with clear economic and patient safety benefits, not because it promised a disruptive shift in surgical paradigms. This limited upside to improving existing procedures rather than creating entirely new ones, relying on adoption within established surgical workflows.

Source: SEC EDGAR Form D filing